11
Participants
Start Date
September 30, 2013
Primary Completion Date
December 31, 2014
Study Completion Date
April 30, 2015
cisplatin
"In Arm I patients receive cisplatin IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II upon disease progression.~In Arm II patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 orally (PO) one time a day (QD) on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~\--------------------------------------------------------------------------------"
laboratory biomarker analysis
correlative studies
pharmacological study
correlative studies
dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI
correlative studies
GDC -0941
Patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 PO QD on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
Vanderbilt-Ingram Cancer Center, Nashville
University of Alabama, Birmingham
University of California, San Francisco, San Francisco
Georgetown University, Washington D.C.
Emory University, Atlanta
University of Chicago, Chicago
Indiana University, Indianapolis
John Hopkins University, Baltimore
Dana Farber Cancer Institute, Boston
University of Michigan, Ann Arbor
Mayo Clinic, Rochester
Memorial Sloan-Kettering Cancer Center, New York
University of North Carolina, Charlotte
University of Pittsburgh, Pittsburgh
Baylor Breast Center, Houston
University of Washington, Seattle
Collaborators (1)
National Cancer Institute (NCI)
NIH
Genentech, Inc.
INDUSTRY
Vanderbilt-Ingram Cancer Center
OTHER